Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity, Inc. RVTY is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup.

The counterweight is valuation. RVTY already trades above its industry, sector and market benchmarks, while software and research-funding volatility keep execution risk in view. That mix favors a selective approach rather than treating the improving outlook as an automatic buy signal.

Revvity’s Growth Outlook Has Clearly Improved

Revvity raised 2026 pro forma revenue guidance to $2.83-$2.86 billion and adjusted earnings guidance to $5.30-$5.40 per share. The company now expects 4%-5% organic growth, up from its prior 3%-4% range.

Diagnostics is doing much of the heavy lifting. Second-quarter pro forma organic revenues rose 11%, with Reproductive Health up in the mid-teens and Immunodiagnostics outside China accelerating to the high single digits. Danaher Corporation DHR also reported improving Life Sciences conditions in its second quarter, adding a useful industry read on recovering demand.

RVTY Still Trades at a Premium to Key Benchmarks

RVTY trades at 22.9X forward 12-month earnings, above the 16.5X Zacks sub-industry multiple, 21.6X sector multiple and 19.9X for the S&P 500. The stock is also above its five-year median of 21.7X.

That premium raises the bar for execution. Medpace Holdings, Inc. MEDP, a global clinical contract research organization serving biotechnology and pharmaceutical customers, provides another way to track R&D spending trends, but Revvity’s own multiple already assumes investors will reward a sustained recovery.

Image Source: Zacks Investment Research

Revvity’s Software and Funding Risks Remain

Life Sciences pro forma organic revenues fell 3% in the second quarter. Software declined about 20% because of contract-renewal timing and difficult comparisons, more than offsetting low-single-digit growth in Life Sciences Solutions.

Academic and government sales also declined in the low single digits. Management expects software to return to strong double-digit growth in the second half, but uneven funding cycles and renewal timing could make that recovery less linear than the headline guidance suggests.

RVTY’s Cash Flow Supports the Portfolio Transition

Second-quarter free cash flow reached $183.8 million, equal to 117% of adjusted net income. Year-to-date free cash flow totaled $299 million, representing 108% conversion.

Revvity also retired a €500 million note in July. Management expects gross leverage to fall below 3X by year-end, while net leverage was 2.5X at quarter-end. That balance-sheet progress gives the company more flexibility as it reinvests in growth initiatives and works toward the planned China Immunodiagnostics divestiture.

Revvity Inc. Free Cash Flow (Quarterly)

Revvity Inc. free-cash-flow-quarterly | Revvity Inc. Quote

RVTY’s Rank Helps, but Style Scores Urge Selectivity

The improving outlook supports the fundamental case, but valuation and mixed operating trends argue against ignoring entry price. The setup looks stronger than it did earlier in the year, yet the risk-reward remains more balanced than the raised guidance alone might imply.

RVTY currently carries a Zacks Rank #3 (Hold), while the Zacks Consensus Estimate for current-year earnings has risen 2.1% over the past four weeks. That combination points to moderately favorable near-term earnings-estimate momentum. While Medpace carries a Zacks Rank #2 (Buy), Danaher carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores are less supportive. Revvity has a Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. Because Style Scores are designed to complement the Zacks Rank, those weaker readings suggest investors may want greater selectivity despite the positive Rank, particularly while the stock trades at a premium valuation.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research